Clinuvel Pharmaceuticals Limited (CLVLF) Investment Research Dashboard
About Clinuvel Pharmaceuticals Limited (CLVLF) stock analysis
Get live CLVLF stock price $6.10, comprehensive Clinuvel Pharmaceuticals Limited stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time CLVLF stock data and investment insights.
Loading chart data...
Clinuvel Pharmaceuticals Limited (CLVLF) Overview
Clinuvel Pharmaceuticals Limited (CLVLF) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, CLVLF trades at $6.10 with a market capitalization of 307.51M . Over the past 52 weeks, CLVLF has traded between $6.10 and $8.60 , with the current price positioned at approximately 0% of this range . The stock curren...
Key Takeaways
- Operates in the Healthcare sector (Biotechnology)
- Market cap: 307.51M
- Current price: $6.10
- 52-week range: $6.10 - $8.60
- P/E ratio: 14.39
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Clinuvel Pharmaceuticals Limited (CLVLF), an Australian biopharmaceutical firm established in Melbourne in 1987, specializes in the creation and global marketing of therapeutic solutions. Its primary focus is on patients suffering from genetic, metab...
Company Information
- CEO
- Philippe Jacques Wolgen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 109
Contact Information
- Website
- https://www.clinuvel.com
- Address
- 535 Bourke Street
- Country
- AU
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 14.4)
✓ Lower volatility stock (Beta: 0.61) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Clinuvel Pharmaceuticals Limited shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Clinuvel Pharmaceuticals Limited
- ⚠Investors should consider how Clinuvel Pharmaceuticals Limited fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
307.51M
P/E Ratio (TTM)
14.39
Beta
0.61
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare CLVLF with peer companies:
- Price
- $3.47+0.00% (1D)
- Market cap
- 251.93M
- Price
- $0.20-2.80% (1D)
- Market cap
- 271.60M
- Price
- $1.71+13.25% (1D)
- Market cap
- 163.42M
- Price
- $0.14+0.00% (1D)
- Market cap
- 273.74M
- Price
- $2.70+50.00% (1D)
- Market cap
- 364.50M
- Price
- $2.90+0.00% (1D)
- Market cap
- 289.23M
- Price
- $0.17-0.98% (1D)
- Market cap
- 282.49M
- Price
- $0.35+219.34% (1D)
- Market cap
- 240.94M
- Price
- $0.05+0.00% (1D)
- Market cap
- 73.69M
- Price
- $1.80+12.71% (1D)
- Market cap
- 438.15M
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
78/100 ⭐⭐⭐⭐⭐
- Overall
- +0.7%
- NYSE
- +0.6%
- NASDAQ
- +0.7%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +2.2% | +3.1% | +4.3% | 19.3 | 98/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.7% | +1.3% | +1.6% | 24.1 | 78/100⭐⭐⭐⭐⭐ |
| Communication Services | +1.4% | -0.7% | +2.9% | 22.2 | 74/100⭐⭐⭐⭐⭐ |
| Consumer Defensive | -0.2% | +1.8% | +0.7% | 29.7 | 64/100⭐⭐⭐⭐ |
| Basic Materials | +0.4% | +1.2% | -0.2% | 25.2 | 61/100⭐⭐⭐⭐ |
| Real Estate | -0.5% | +0.0% | -2.5% | 29.2 | 43/100⭐⭐⭐ |
| Energy | -2.1% | -3.7% | -4.1% | 19.1 | 39/100⭐⭐ |
| Utilities | -1.0% | +0.0% | -4.4% | 26.8 | 37/100⭐⭐ |
| Industrials | +0.6% | +0.4% | -9.9% | 30.1 | 23/100⭐ |
| Consumer Cyclical | +0.5% | -1.5% | -5.8% | 43.0 | 18/100⭐ |
| Technology | +0.6% | -1.6% | -7.2% | 40.7 | 15/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.